Population Genomic Screening Programs Market Report 2026

Population Genomic Screening Programs Market Overview

• Population Genomic Screening Programs market size has reached to $3.91 billion in 2025 • Expected to grow to $7.7 billion in 2030 at a compound annual growth rate (CAGR) of 14.6% • Growth Driver: Rising Demand For Personalized Medicine Driving Growth In The Market Due To Advances In Genomics Enabling Targeted Treatments • Market Trend: Leading Companies Driving Innovation In Genomic Health Programs • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Population Genomic Screening Programs Market?

Population genomic screening programs are organized public health initiatives that offer genetic testing to large groups of individuals, often regardless of personal or family history, to identify pathogenic genetic variants associated with actionable health conditions. The primary goal of these programs is early detection of genetic risk to enable timely prevention, surveillance, or treatment and thereby reduce disease morbidity and mortality at the population level. The main program types of population genomic screening programs include newborn screening, adult screening, carrier screening, pharmacogenomics, and other program types. Newborn screening refers to programs designed to identify genetic conditions early in life to enable timely intervention. The program models include national screening programs, regional screening programs, institution-based screening, and direct-to-consumer screening. The technologies include next generation sequencing, microarray, polymerase chain reaction, and other technologies. The key applications of rare disease detection, cancer risk assessment, pharmacogenomics, chronic disease prediction, and other applications, while the end-users includes hospitals, research institutes, government agencies, diagnostic laboratories, and other end-users.

What Is The Population Genomic Screening Programs Market Growth Forecast?

The population genomic screening programs market size is expected to see rapid growth in the next few years. It will grow to $7.7 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to expansion of adult and carrier screening programs, adoption of ai-based genomic interpretation tools, integration with digital health platforms, increasing demand for personalized medicine, investment in population genomic research. Major trends in the forecast period include population-wide genetic risk assessment, integration with electronic health records (ehr), ai-driven variant interpretation, personalized preventive health programs, data security & privacy compliance.

Global Population Genomic Screening Programs Market Segmentation

1) By Program Type: Newborn Screening, Adult Screening, Carrier Screening, Pharmacogenomics, Other Program Types 2) By Program Model: National Screening Programs, Regional Screening Programs, Institution Based Screening, Direct To Consumer Screening 3) By Technology: Next Generation Sequencing, Microarray, Polymerase Chain Reaction, Other Technologies 4) By Application: Rare Disease Detection, Cancer Risk Assessment, Pharmacogenomics, Chronic Disease Prediction, Other Applications 5) By End-User: Hospitals, Research Institutes, Government Agencies, Diagnostic Laboratories, Other End-Users Subsegments: 1) By Newborn Screening: Rare Disease Screening, Metabolic Disorder Screening, Immunodeficiency Disorder Screening, Neurological Disorder Screening, Endocrine Disorder Screening 2) By Adult Screening: Hereditary Cancer Risk Screening, Cardiovascular Genetic Risk Screening, Neurodegenerative Disease Risk Screening, Preventive Health Risk Screening, Late Onset Genetic Disorder Screening 3) By Carrier Screening: Preconception Carrier Screening, Prenatal Carrier Screening, Expanded Carrier Screening, Recessive Disorder Carrier Screening, Population Based Carrier Screening 4) By Pharmacogenomics: Drug Response Prediction Testing, Adverse Drug Reaction Risk Testing, Dose Optimization Testing, Therapeutic Selection Testing, Medication Safety Testing 5) By Other Program Types: Polygenic Risk Assessment Programs, Predictive Genomic Health Programs, Preventive Genomic Screening Programs, Population Risk Stratification Programs, Research Based Genomic Screening Programs

What Is The Driver Of The Population Genomic Screening Programs Market?

The growing demand for personalized medicine is expected to propel the growth of the population genomic screening programs market. Personalized medicine involves tailoring medical treatments and healthcare decisions based on an individual’s genetic, environmental, and lifestyle characteristics to improve therapeutic effectiveness and safety. The increasing adoption of personalized medicine is driven by advances in genomics and molecular diagnostics, which enable clinicians to better understand genetic variability and deliver more precise, targeted therapies that enhance patient outcomes and reduce adverse effects. Population genomic screening programs play a foundational role in advancing personalized medicine by identifying genetic variations and disease-associated risk factors across large and diverse populations. These programs support early disease risk detection, stratification of patient populations, and the development of tailored prevention and treatment strategies at both individual and public health levels. For instance, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that in 2023 the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from six approvals in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the population genomic screening programs industry.

Key Players In The Global Population Genomic Screening Programs Market

Major companies operating in the population genomic screening programs market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Illumina Inc., Natera Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Fulgent Genetics Inc., Ambry Genetics Corporation, Pacific Biosciences of California Inc., Color Genomics Inc., Helix OpCo Inc., Personalis Inc., CENTOGENE N.V., ProPhase Labs Inc., DNAnexus Inc., Genomics England Limited, Eurofins Genomics Germany GmbH, Sema4 Inc., Mapmygenome India Private Limited, Gencove Inc.

Global Population Genomic Screening Programs Market Trends and Insights

Major companies operating in the population genomic screening programs market are focusing on developing innovative solutions such as, hereditary risk assessment to enable early detection of genetic predispositions, guide personalized prevention strategies, and improve long-term health outcomes. Hereditary risk assessment refers to the evaluation of an individual’s likelihood of developing certain genetic disorders or diseases based on their inherited genetic variants and family medical history. For instance, in November 2023, Helix OpCo, LLC, a US-based population genomics and clinical technology company, partnered with Cone Health, a US-based not-for-profit network of healthcare providers, to launch a population genomics initiative to advance precision medicine in North Carolina. This program deploys Helix's end-to-end platform to deliver actionable precision medicine insights, enabling earlier interventions, community wellness efforts, and health equity improvements across Alamance, Forsyth, Guilford, Rockingham, and Randolph counties and beyond.

What Are Latest Mergers And Acquisitions In The Population Genomic Screening Programs Market?

In August 2024, Natera Inc., a US-based biotechnology company, acquired Invitae Corp. for an undisclosed amount. With this acquisition, Natera aims to expand its capabilities in non-invasive prenatal and carrier screening, enhancing its service offerings and supporting more patients and providers. Invitae Corp. is a US-based medical genetics company that offers population genomic screening programs.

Regional Insights

North America was the largest region in the population genomic screening programs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Population Genomic Screening Programs Market?

The population genomic screening programs market includes revenues earned by entities by providing services such as carrier screening, pharmacogenomic testing, and newborn genomic screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Population Genomic Screening Programs Market Report 2026?

The population genomic screening programs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the population genomic screening programs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.